Page last updated: 2024-12-11
tomoxiprole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6917745 |
| CHEMBL ID | 347043 |
| SCHEMBL ID | 525023 |
| MeSH ID | M0127284 |
Synonyms (21)
| Synonym |
|---|
| mdl-035 |
| tomoxiprole |
| tomoxiprolum [latin] |
| brn 5975068 |
| tomoxiprole [inn] |
| 2-(4-methoxyphenyl)-3-(1-methylethyl)-3h-naphth(1,2-d)imidazole |
| 3h-naphth(1,2-d)imidazole, 2-(4-methoxyphenyl)-3-(1-methylethyl)- |
| tomoxiprol [spanish] |
| 3-isopropyl-2-(p-methoxyphenyl)-3h-naphth(1,2-d)imidazole |
| CHEMBL347043 |
| 2-(4-methoxyphenyl)-3-propan-2-ylbenzo[e]benzimidazole |
| tomoxiprolum |
| ez948t2878 , |
| unii-ez948t2878 |
| 76145-76-1 |
| SCHEMBL525023 |
| 3-(1-methylethyl)-2-(4-methoxyphenyl)-3h-naphth[1,2-d]imidazole |
| 3-isopropyl-2-(4-methoxyphenyl)-3h-naphtho[1,2-d]imidazole |
| mdl 035 |
| Q27277446 |
| DTXSID201032783 |
Research Excerpts
Overview
Tomoxiprole is a nonsteroidal anti-inflammatory compound. It was reported to have low ulcerogenic potential.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tomoxiprole is a nonsteroidal anti-inflammatory compound that was reported to have low ulcerogenic potential, a quality that would be expected of a cyclooxygenase-2-selective inhibitor, and, in fact, we find it is selective for this isozyme. " | ( Tomoxiprole selectively inhibits cyclooxygenase-2. Billah, MM; Carruthers, NI; Egan, RW; She, HS; West, RE; Williams, SM, 1997) | 3.18 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " A metabolic first pass reduced the extent of oral bioavailability of the parent compound to about half, while absorption (total 14C data) was estimated to be complete." | ( Pharmacokinetics and metabolism of tomoxiprole, a new analgesic antiinflammatory agent, in the rat. Assandri, A; Bernareggi, A; Perazzi, A; Ripamonti, A; Toja, E, ) | 0.41 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID184783 | Peroral dose showing lethal effects in 50% of the rats with carrageenan -induced paw edema | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID170950 | Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID196877 | Compound was evaluated for its gastroulcerogenic effect in rats at a peroral dose of 200 mg/kg | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID170141 | Compound was evaluated for its antipyretic activity by antipyresis effect in comparison with that of Aspirin. | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID194099 | Antiinflammatory activity was measured as the percentage inhibition of edema in carrageenan induced rat paw after peroral administration of 100 mg/kg of compound | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID187055 | Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID170140 | Compound was evaluated for its analgesic activity by Randall-Selitto test in comparison with that of Aspirine | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID182166 | Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 100 mg/kg administered orally | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID194278 | Compound was evaluated for its antiinflammatory activity in the cotton pellet induced granuloma(CPG) in normal rats at the dose 200 mg/kg p.o. | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| AID183669 | Antiinflammatory activity measured as the percentage inhibition of edema in carrageenan induced rat paw after peroral administration of 200 mg/kg of compound | 1984 | Journal of medicinal chemistry, May, Volume: 27, Issue:5 | 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||